NODEN PHARMA
SpecialtyNODEN PHARMA is a specialty pharmaceutical company with 2 FDA-approved products.
NODEN PHARMA's Key Drugs
NODEN PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
NODEN PHARMA's Recent FDA Approvals
New NDA/BLA approvals for NODEN PHARMA over the last two years — novel drugs only, excluding generics and label supplements.
NODEN PHARMA's Therapeutic Areas
Disease areas where NODEN PHARMA has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
NODEN PHARMA Pipeline Snapshot
Active clinical trials for NODEN PHARMA across all therapeutic areas, from ClinicalTrials.gov.
Phase 3 Readout Calendar Pro
1 Phase 3 trial with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2008-01-18
- Latest
- 2020-09-28
- Applications
- 2